Results 321 to 330 of about 3,443,356 (396)

Metabolic subtyping reveals PDIK1L as a dual-functional regulator of progression and PARP inhibitor sensitivity in prostate cancer. [PDF]

Front Cell Dev Biol
Wang Z, Ge Q, Aihetaimujiang A, Zhang J, Lu J, Yang J, Chen Y, Qin B, Zhang H, Xu WH, Ye D.   +10 more
europepmc   +1 more source

Data from Crizotinib Enhances PARP Inhibitor Efficacy in Ovarian Cancer Cells and Xenograft Models by Inducing Autophagy

Janice M. Santiago‐O’Farrill, Alicia Blessing Bollu, Hailing Yang, Vivian Orellana, Marc A. Pina, Xudong Zhang, Jinsong Liu, Robert C. Bast, Zhen Lü   +8 more
openalex   +1 more source

Targeting EZH2 in Cancer: From Molecular Mechanisms to Clinical Translation

MedComm – Oncology, Volume 5, Issue 2, June 2026.
The abnormal overexpression or gain‐of‐function mutations of EZH2 play a significant role in cancer occurrence and progression, highlighting the importance and potential of EZH2 as a cancer biomarker. Therefore, screening for effective and safe small‐molecule inhibitors, degraders, and natural compounds targeting EZH2 through preclinical cancer models ...
Xi Zhong, Jieni Li, Mingxuan Pan, Xiaoxue Ke, Hongjuan Cui   +4 more
wiley   +1 more source

Differential PARP inhibitor responses in BRCA1-deficient and resistant cells in competitive co-culture. [PDF]

PLoS One
Soetomo SA, Sharp MF, Crismani W.
europepmc   +1 more source

COMPUTATIONAL DRUG DESIGN AND MOLECULAR DYNAMICS OF PHENYL BENZAMIDE DERIVATIVES AS PARP-1 INHIBITORS FOR BREAST CANCER THERAPY

Pulla Prudvi Raj, Divya Jyothi Palati, Praveen Thaggikuppe Krishnamurthy, Gowramma Byran   +3 more
openalex   +2 more sources

Oncofetal Biology: From Fundamental Mechanisms to Emerging Therapeutic Opportunities

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Oncofetal biology provides a transformative framework for understanding cancer initiation, progression, and therapeutic intervention. This review synthesizes the core molecular mechanisms connecting embryonic development and tumorigenesis from a multidisciplinary standpoint and outlines future research trajectories and clinical applications, and we aim
Yang Liu, Kaifeng Niu, Qingran Kong, Shaorong Gao   +3 more
wiley   +1 more source

Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in BRCA mutant cancer cells. [PDF]

Nucleic Acids Res
Ribeiro J, Hansen K, van Beek L, Stubbs C, Frigola J, Talbot S, Bentouati S, Hall J, Wijnhoven PWG, Armenia J, Schimpl M, Forment JV, Albertella MR, O'Connor MJ, Illuzzi G.   +14 more
europepmc   +1 more source

Supplementary Figure S4 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma

Louise Ramos, Sarah Truong, Beibei Zhai, Jay Joshi, Fariba Ghaidi, Michael M. Lizardo, Taras Shyp, Sonia H.Y. Kung, Alireza M. Rezakhanlou, Htoo Zarni Oo, Hans Adomat, Stéphane LeBihan, Colin C. Collins, Jeffrey Bacha, Dennis Brown, John Langlands, Wang Shen, Nada Lallous, Poul H. Sorensen, Mads Daugaard   +19 more
openalex   +1 more source

CHD4 Orchestrates Chromatin Remodeling to Activate the c‐Myc Signaling Pathway in Cancer Pathogenesis

MedComm – Oncology, Volume 5, Issue 2, June 2026.
CHD4 plays an essential role as an epigenetic regulator in the pathogenesis of multiple myeloma. The chromatin remodeling protein initially resolves G‐quadruplex (G4) secondary structures within the c‐Myc promoter region, thereby enhancing chromatin accessibility and promoting transcriptional activation.
Pinggang Ding, Yuhao Cao, Zihao Liu, Jingru Xie, Lingling Liu, Shanliang Sun, Xichao Yu, Zhendong Deng, Zhimin Fan, Ye Yang, Chunyan Gu   +10 more
wiley   +1 more source

The Real-World Impact of PARP Inhibitor Maintenance Therapy in High Grade Serous Tubo-Ovarian and Peritoneal Cancers. [PDF]

Cancers (Basel)
Al-Ani M, Baraka B, Mathiyalagan N, Sarwar MA, Segaran A, Abuzahra W, Radford A, Buxton K, Seneviratne L, Sundar S, Anand A, Nunns D, Williamson K, Wormald B, Gajjar K, Madhusudan S.   +15 more
europepmc   +1 more source